Telix Pharmaceuticals Receives FDA Fast Track Designation for Prostate Cancer Imaging Program

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Telix Pharmaceuticals' BiPASS program, which evaluates 68Ga-PSMA-PET imaging alongside MRI for pre-biopsy prostate cancer detection. This designation aims to expedite the development and review of the imaging agent, recognizing its potential to address an unmet medical need by enabling an imaging-first approach to initial prostate cancer diagnosis and potentially reducing unnecessary invasive biopsies.